Pnc Financial Services Group, Inc. Crinetics Pharmaceuticals, Inc. Transaction History
Pnc Financial Services Group, Inc.
- $148 Billion
- Q4 2024
A detailed history of Pnc Financial Services Group, Inc. transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Pnc Financial Services Group, Inc. holds 2,707 shares of CRNX stock, worth $95,313. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2,707
Previous 2,520
7.42%
Holding current value
$95,313
Previous $128,000
7.81%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding CRNX
# of Institutions
251Shares Held
86.3MCall Options Held
23.3KPut Options Held
44.3K-
Vanguard Group Inc Valley Forge, PA9.09MShares$320 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA6.95MShares$245 Million0.07% of portfolio
-
Black Rock Inc. New York, NY6.23MShares$219 Million0.01% of portfolio
-
Driehaus Capital Management LLC Chicago, IL5.89MShares$207 Million2.95% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD4.94MShares$174 Million0.03% of portfolio
About Crinetics Pharmaceuticals, Inc.
- Ticker CRNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 53,752,800
- Market Cap $1.89B
- Description
- Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...